Table 1

Clinical picture, therapy, and follow-up for each patient

Case no.Age (median 64 y)/sex ratio (5:2 male/female)Sites of involvement at diagnosisInitial treatmentResponseRelapse, monthsSites of relapseTherapy at relapseFollow-up, months
Skin (n = 21)BM (n =10)Peripheral blood (n =9)Lymph node (n =5)Other (n =2)
164/MMu++ALL-type*CR11S/BM/BCHTDOD 23
283/MD+++NoneDOD 3
338/MMu+SCTCR17S/BM/B/LyCHTDOD 20
467/FDALL-type*PR5SCHTAWD 11
584/FDmCHTPR4BDOD 6
664/MD++ALL-typeCR10S/BM/BCHTDOD 26
719/MMuNHL-type§CR36SSCTAWD 72
862/MMu+++ALL-type*CRADF 13
961/MMuNHL-type§CR30S/BM/B/LyCHTDOD 35
1083/MD++MALTNHL-type§PR8S/BM/B/OCHTDOD 10
1140/MLmCHT + RTPR20BM/BCHTDOD 30
1260/MD+SCTCRDTR 60
1376/MLRTCR8BMCHTAWD 13
149/FD++ALL-type*CRADF 12
1558/MDALL-type*CRADF 28
1679/MLRTCRADF 14
1775/FDALL-type*CRADF 8
1839/FLALL-type*CRDTR 12
1966/FMu++NHL-type§PR5S/BM/B/OCHTDOD 20
2064/MD+++MALTALL-type*PR4S/BSCTDOD 12
2183/ML+++NoneDOD 1
  • BM indicates bone marrow; Mu, multiple noncontiguous skin lesions; D, diffuse skin involvement; L, localized skin disease; Ly, lymph node; MALT, mucosa-associated lymphoid tissue; O, other; B, peripheral blood; ALL, acute lymphoblastic leukemia; SCT, allogeneic stem cell transplantation; mCHT, monochemotherapy; NHL, non-Hodgkin lymphoma; RT, radiotherapy; CR, complete remission; —, not available; PR, partial remission; S, skin; CHT, chemotherapy; DOD, dead of disease; AWD, alive with disease; ADF, alive disease-free; and DTR, death therapy-related.

  • * Hyper-CVAD regimen (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with high-dose methotrexate and cytarabine).

  • Hydroxyurea.

  • IVA regimen (ifosfamide, vincristine, actinomycin-D).

  • § CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisolone).

  • This patient had skin-limited disease at diagnosis, but she refused treatment until 8 months later when bone marrow involvement developed.